Does Cancer-Related Weight Loss Reduce Immunotherapy Efficacy?

Successful immunotherapies have become important in malignant melanoma, lung, kidney, bladder, head and neck cancers and Hodgkin lymphoma. Designed to activate immunity against cancer, immunotherapiesdo not work equally in every patient. Researchers identified cancer-related weight loss as potentially reducing efficacy.
Weight loss and poor appetite in cancer are known as cancer cachexia . It appears earlier in certain cancers, such as pancreatic cancer. Recent research has examined how it affects treatment response.
In November 2016, the respected journal Cell Metabolismpublished research showing that metabolic changes may reduce immunotherapy efficacy . Mice with early cancer but no cachexia were studied, comparing efficacy before and after cachexia.
According to the Research Results:
- Cancer cells affected liver function through interleukin 6 (IL-6). The liver stores nutrients needed for energy. IL-6 shuts down mechanisms producing energy during low intake. Inadequate energy production triggers a hormonal response preventing anticancer immunity.
What Does This Study Mean Clinically?
- Similar human experiments may enable treatments correcting metabolic changes,
- Tests predicting which patients benefit from immunotherapy may be developed,
- The study guides development of effective immunotherapies also targeting cancer cachexia.
Sources
Tumour induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumour Immunity.
Cell Metabolism.2016, 24(5),672-684
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.